Navigation Links
Shionogi Announces FDA Approval of KAPVAY™ - The First and Only Therapy Approved for Use with Stimulant Medication for the Treatment of ADHD
Date:10/4/2010

highest value on patients. Shionogi's Research and Development currently targets three therapeutic areas: Infectious Diseases, Pain, and Metabolic Syndrome. The Company has provided such innovative medicines as Crestor and Doripenem, which have been successfully delivered to millions of patients. In addition, Shionogi is engaged in new research areas such as allergy and cancer. Contributing to the health of patients around the world through development in these therapeutic areas is Shionogi's primary goal. For more details, please visit www.shionogi.co.jp. For more information on Shionogi Inc., headquartered in Florham Park, NJ, please visit www.shionogi-inc.com.

Forward Looking Statements

This announcement contains forward-looking statements. These statements are based on expectations in light of the information currently available, assumptions that are subject to risks and uncertainties which could cause actual results to differ materially from these statements. Risks and uncertainties include general domestic and international economic conditions such as general industry and market conditions, and changes of interest rate and currency exchange rate. These risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, completion and discontinuation of clinical trials; obtaining regulatory approvals; claims and concerns about product safety and efficacy; technological advances; adverse outcome of important litigation; domestic and foreign healthcare reforms and changes of laws and regulations. Also for existing products, there are manufacturing and marketing risks, which include, but are not limited to, inability to build production capacity to meet demand, unavailability of raw materials and entry of competitive products. The company disclaims any
'/>"/>

SOURCE Shionogi Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Stallergenes and Shionogi Sign Exclusive Partnership Agreements for Immunotherapy Tablets in Japan
2. BioCrysts Partner Shionogi Receives Marketing & Manufacturing Approval For Peramivir in Japan
3. Orexigen® Therapeutics Announces Upcoming Data Presentations at the 28th Annual Scientific Meeting of The Obesity Society
4. Intra-Cellular Therapies Announces Positive Results with ITI-002 in Pre-Clinical Models of Parkinsons Disease
5. Bioheart, Inc. Announces Loan to be Assumed by Seaside
6. Shire Announces Results of the Tender Offer for Movetis NV and Commencement of Squeeze-Out Tender Period
7. IGEN AMENDS DISTRIBUTION AGREEMENT AND ANNOUNCES FIRST SPECTRUM BUILD-OUT
8. Crescendo Biologics Announces First Triple Knockout Mouse
9. Pepscan Therapeutics Announces Establishment of Scientific Advisory Board
10. Jiangbo Pharmaceuticals Announces Conference Call to Discuss Results for Fourth Quarter Fiscal 2010
11. Cellectis Bioresearch Announces Availability of Research Kits Through New Online E-Store
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... January 22, 2015 The laboratory information ... has witnessed a number of technological advancements due to ... requirements, growing need to integrate healthcare systems, and increasing ... challenges in system integration. Key players in the market ...
(Date:1/22/2015)... Pipette.com has added the Eppendorf Centrifuge ... of Eppendorf products. , The Eppendorf Centrifuge 5424/5424 R ... R and receive the following:, ,     Free ... Eppendorf Reference 2 ,     3 Free boxes ...
(Date:1/22/2015)... Controlled Substance Compliance Services (CSCS), a project managed ... legal requirements around using controlled substances in pharmaceutical research, ... their international operations expand and become increasingly complex, large ... a result of the first phase of the CSCS ...
(Date:1/22/2015)... 22 de enero de 2015  El Dr. Paul ... llamada a nominaciones para 2015. Este prestigioso premio reconoce ... tiene el potencial para hacer, contribuciones destacadas para la ... hasta el 15 de marzo de 2015 a través ...
Breaking Biology Technology:Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 2Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 3Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 4Eppendorf Announces Promotional Bundle Which Includes: Eppendorf Centrifuge 5424, 3-Pack of Pipettes, and Tips - Available Now at Pipette.com 2Global Compliance Service for Controlled Substances to Expand to China 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 3El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 4
... $2.25 to $2.35., ST. LOUIS, Oct. 23 , HIGHLIGHTS:, ... periods in 2006):, -- Strongest Quarterly Sales Growth in 2007: ... prior quarters, performance, with reported quarterly growth ... high sales achieved in Q2 2007. Organic ...
... Roche Releases Positive Phase I Results for R1507, ... positive results from a Phase I study of R1507 ... R1507 is a human,monoclonal antibody targeting the insulin-like growth ... Genmab. Nine of 34 adult patients with solid ...
... Va., Oct. 23 PRA International,(Nasdaq: PRAI ) ... of therapeutic expertise and a specialist in oncology and,hematology, ... in oncology on Thursday, Nov. 8, 2007 at 11:30 ... Berger will,recommend ways to mitigate risk in terms of ...
Cached Biology Technology:Sigma-Aldrich (Nasdaq: SIAL) Q3 2007 Sales Increase 14.0%, Yielding Diluted EPS of $.54. 2Sigma-Aldrich (Nasdaq: SIAL) Q3 2007 Sales Increase 14.0%, Yielding Diluted EPS of $.54. 3Sigma-Aldrich (Nasdaq: SIAL) Q3 2007 Sales Increase 14.0%, Yielding Diluted EPS of $.54. 4Sigma-Aldrich (Nasdaq: SIAL) Q3 2007 Sales Increase 14.0%, Yielding Diluted EPS of $.54. 5Sigma-Aldrich (Nasdaq: SIAL) Q3 2007 Sales Increase 14.0%, Yielding Diluted EPS of $.54. 6Sigma-Aldrich (Nasdaq: SIAL) Q3 2007 Sales Increase 14.0%, Yielding Diluted EPS of $.54. 7Sigma-Aldrich (Nasdaq: SIAL) Q3 2007 Sales Increase 14.0%, Yielding Diluted EPS of $.54. 8Sigma-Aldrich (Nasdaq: SIAL) Q3 2007 Sales Increase 14.0%, Yielding Diluted EPS of $.54. 9Sigma-Aldrich (Nasdaq: SIAL) Q3 2007 Sales Increase 14.0%, Yielding Diluted EPS of $.54. 10Sigma-Aldrich (Nasdaq: SIAL) Q3 2007 Sales Increase 14.0%, Yielding Diluted EPS of $.54. 11Sigma-Aldrich (Nasdaq: SIAL) Q3 2007 Sales Increase 14.0%, Yielding Diluted EPS of $.54. 12Sigma-Aldrich (Nasdaq: SIAL) Q3 2007 Sales Increase 14.0%, Yielding Diluted EPS of $.54. 13Sigma-Aldrich (Nasdaq: SIAL) Q3 2007 Sales Increase 14.0%, Yielding Diluted EPS of $.54. 14Sigma-Aldrich (Nasdaq: SIAL) Q3 2007 Sales Increase 14.0%, Yielding Diluted EPS of $.54. 15Sigma-Aldrich (Nasdaq: SIAL) Q3 2007 Sales Increase 14.0%, Yielding Diluted EPS of $.54. 16Sigma-Aldrich (Nasdaq: SIAL) Q3 2007 Sales Increase 14.0%, Yielding Diluted EPS of $.54. 17Sigma-Aldrich (Nasdaq: SIAL) Q3 2007 Sales Increase 14.0%, Yielding Diluted EPS of $.54. 18Sigma-Aldrich (Nasdaq: SIAL) Q3 2007 Sales Increase 14.0%, Yielding Diluted EPS of $.54. 19Sigma-Aldrich (Nasdaq: SIAL) Q3 2007 Sales Increase 14.0%, Yielding Diluted EPS of $.54. 20Phase I Results Announced for R1507 From Genmab's Collaboration With Roche 2Phase I Results Announced for R1507 From Genmab's Collaboration With Roche 3PRA International to Present Audioconference on Oncology Research - Nov. 8 2
(Date:12/17/2014)... Va. , Dec. 15, 2014 The Defense ... easier to detect and prevent counterfeit microcircuits from entering ... started performing an in-house microcircuit anti-counterfeit initiative dubbed DNA ... microcircuits while increasing their reliability throughout the supply chain. ...
(Date:12/17/2014)... Dec. 16, 2014 Valencell, a leader in performance ... technology to industry leaders such as Intel, Jabra, Atlas, ... biometric wearable products. These products will be showcased at ... Las Vegas . "Our partners ...
(Date:12/17/2014)... DENVER , Dec. 16, 2014  Automation is fundamentally ... evident than at international borders. Over the past decade, ... veteran travelers to self process through border control via ... increasing number of airports, seaports, and land borders across ...
Breaking Biology News(10 mins):Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 2Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 3Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2
... suppression therapy to prevent T cell-mediated rejection. These ... undesirable side effects. Therefore, specific suppression of the ... needed. , It was known that anergic T ... to antigen stimulation) generated in an artificial environment ...
... culprits in delivering pollutants ?through their guano ?to seemingly ... The most common form of wildlife in the Arctic, ... contaminants to some coastal ecosystems, the researchers found. "The ... mercury and DDT to as much as 60 times ...
... biggest questions in modern oceanography is how animals in ... at the Monterey Bay Aquarium Research Institute (MBARI) recently ... least for animals that live on the deep seafloor ... of hours of deep-sea video, Bruce Robison and his ...
Cached Biology News:Industrial contaminants spread by seabirds in High Arctic, new Canadian study shows 2'Sinkers' provide missing piece in deep-sea puzzle 2'Sinkers' provide missing piece in deep-sea puzzle 3'Sinkers' provide missing piece in deep-sea puzzle 4
EGTA, 50 g. Ethylene glycol-O,O-bis-[2-amino-ethyl]-N,N,N,N,-tetraacetic acid.Assay: > 99.0%. Category: Nucleotides & Enzymes & Biochemicals, Ultrapure Biochemicals ....
Request Info...
RABBIT ANTI NEOPTERIN...
... Dog serum is collected from fasted mixed breed, ... Available Anticoagulants: N-02: Citrate ... K2EDTA N-08: Potassium Oxalate N-10: ... N-05: ACD N-07: CPD ...
Biology Products: